CV
GRTS

Clarus Ventures’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Clarus Ventures’s Portfolio GRTS Stock Details GRTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$36.6M Buy
+2,567,445
New +$36.6M 8.59% 5

Other funds holding GRTS

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Clarus Ventures's GRTS Position: Q3 2018 in Review

Clarus Ventures opened a new position in Gritstone bio, Inc. Common Stock (GRTS) in Q3 2018: 2,567,445 shares worth $36.6M. The stake represents 8.59% of the portfolio and ranks #5 among its holdings.

43 funds tracked by Wall St. Rank hold GRTS as of Q3 2018.

  • Clarus Ventures held 2,567,445 shares of Gritstone bio, Inc. Common Stock worth $36.6M as of Q3 2018.
  • Gritstone bio, Inc. Common Stock was a new Clarus Ventures position in Q3 2018.
  • Gritstone bio, Inc. Common Stock made up 8.59% of Clarus Ventures's portfolio in Q3 2018, its #5 holding.
  • 43 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q3 2018.

Based on Clarus Ventures's 13F filing for Q3 2018, filed 14 Nov 2018.